/ 22 Shares
30-Jul-2024 - 01-Aug-2024
₹ 646 - ₹ 679
₹ 14938.00
22
27,368,151
Face Value - ₹ 2/- Per Share
Listing at NSE BSE
123,292 Application Required in Retail for 1 Time.
Registrar : Link Intime India Private Ltd
Fresh Issue of up to Rs. 680 Crore and Offer for Sale of Up to 17,330,435 Equity Shares
Category | % | Shares/Amount |
---|---|---|
QIB | 75% | 20,343,188 Shares Rs.1381.30 Cr |
HNI 1 | 5% | 1,356,212 Shares Rs.92.09 Cr @ 4403 Form 1X |
HNI 2 | 10% | 2,712,425 Shares Rs.184.17 Cr @ 8807 Form 1X |
Retail | 10% | 2,712,424 Shares Rs.184.17 Cr @ 123292 Form 1X |
Employee | 0% | 243,902 Shares Rs.15.00 Cr |
BRLMs: Axis Capital, ICICI Securities, Citigroup Global Markets India, Ambit Pvt. Ltd
Retail (Upto 2 Lakh) | HNI (2 Lakh to 10 Lakh) | HNI (Above 10 Lakh) |
---|---|---|
123292 Form 1X | 4403 Form 1X | 8807 Form 1X |
Category | Lots | Shares | Amount |
---|---|---|---|
Retail (Upto 2 Lakh) | 1 | 22 | ₹ 14,938 |
Retail (Upto 2 Lakh) | 13 | 286 | ₹ 194,194 |
S-HNI (2 Lakh to 10 Lakh) | 14 | 308 | ₹ 209,132 |
S-HNI (2 Lakh to 10 Lakh) | 66 | 1452 | ₹ 985,908 |
B-HNI (Above 10 Lakh) | 67 | 1474 | ₹ 1,000,846 |
01-Aug-2024 16:20
Category | Book Size | Subscription | No. of Times |
---|---|---|---|
QIB | 8,137,276 ₹ 552.52 Cr. | 733,117,770 ₹ 49778.70 Cr. | 90.09x |
HNI (<10 LAKH) | 1,356,212 ₹ 92.09 Cr. | 41,900,298 ₹ 2845.03 Cr. | 30.90x |
HNI2 (>10 LAKH) | 2,712,425 ₹ 184.17 Cr. | 128,649,664 ₹ 8735.31 Cr. | 47.43x |
RETAIL | 2,712,424 ₹ 184.17 Cr. | 53,570,418 ₹ 3637.43 Cr. | 19.75x |
EMP | 243,902 ₹ 16.56 Cr. | 973,038 ₹ 66.07 Cr. | 3.99x |
Total | 15,162,239 | 958,211,188 | 63.20x |
Category | Book Size | Subscription | No. of Times |
---|---|---|---|
QIB | 8,137,276 ₹ 552.52 Cr. | 733,117,770 ₹ 49778.70 Cr. | 90.09x |
HNI (<10 LAKH) | 1,356,212 ₹ 92.09 Cr. | 41,900,298 ₹ 2845.03 Cr. | 30.90x |
HNI2 (>10 LAKH) | 2,712,425 ₹ 184.17 Cr. | 128,649,664 ₹ 8735.31 Cr. | 47.43x |
RETAIL | 2,712,424 ₹ 184.17 Cr. | 53,570,418 ₹ 3637.43 Cr. | 19.75x |
EMP | 243,902 ₹ 16.56 Cr. | 973,038 ₹ 66.07 Cr. | 3.99x |
Total | 15,162,239 | 958,211,188 | 63.20x |
*Excluding Anchor
Total No. of Application Approx : ~2136044 (17.33 Appwise)
Disclaimer: The above-mentioned information / data are sourced from the websites of National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) and are subject to change on real time basis. For updated information / data you can visit their respective website. The information / data provided herein above are for information purpose only and provided "AS IS" and "AS AVAILABLE" basis and without warranty, express or implied. We do not guarantee or warrant the accuracy, adequacy or completeness of the information received through the said websites. “We” hold not responsibility of any kind as regard to any discrepancies, errors, omissions, losses or damages. “We” including its affiliates and any of its officers, directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of information / data received through the said websites. The recipient alone shall be fully responsible / are liable for any decision taken on the basis of such information / data. All recipients should before acting upon the said information make their own investigation, seek appropriate professional advice.
The company’s CDMO business client base comprised of 1,524 Indian and MNC pharmaceutical and wellness companies as on March 31st,2024 as against 1,386 as of March 31, 2022. The diverse client base includes pharmaceutical companies, nutraceutical companies, cosmo-derma companies, wellness companies, e-commerce companies, healthcare providers and central and state government entities. The company manufactured formulations for 26 of the leading 30 pharmaceutical companies in terms of sales in India, in FY2024.
The company has a longstanding relationship with its clients. The company has benefitted from repeat orders in the past 5 years from 38 of its 50 largest clients in terms of revenue, as of March 31, 2024. The company’s 50 largest clients in terms of revenue have a legacy of 10 plus years, and their revenue contribution has grown from ?1,354.8.5 Cr during FY 2022 to ?1,441.54 Cr during FY2024.
Competitive Strength
Business Strategies
Sanjeev Jain is the Managing Director of the Company. Sandeep Jain is the Managing Director of the Company. Sanjay Sinha is a Whole Time Director and President, Operations of the Company. Sunil Kumar Thakur is a Non-Executive Director of the Company. Kewal Kundanlal Handa is an Independent Director of the Company. Satwinder Singh is an Independent Director of the Company. Matangi Gowrishankar is an Independent Director of the Company. Matangi Gowrishankar is an Independent Director of the
Akums Drugs and Pharmaceuticals Limited's revenue increased by 13.81% and profit after tax (PAT) dropped by -99.19% between the financial year ending with March 31, 2024 and March 31, 2023.
Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
Assets | 3,516.37 | 3,266.53 | 3,069.05 |
Revenue | 4,212.21 | 3,700.93 | 3,694.52 |
Profit After Tax | 0.79 | 97.82 | -250.87 |
Net Worth | 709.50 | 717.19 | 621.98 |
Reserves and Surplus | 861.01 | 868.70 | 787.79 |
Total Borrowing | 491.56 | 536.97 | 357.95 |
Amount in ? Crore |
The Company proposes to utilize the Net Proceeds towards the funding of the following objects:
Once you create your account, Login to Us.
Under IPO Section, you will be able to see a list of Ongoing IPOs, where you can click on apply button.
Add quantity of shares to apply – Maximum 3 bids are allowed (For retail category – max amount Rs.2,00,000/-).
Enter your UPI ID and you will receive mandate on your UPI App.
Once you accept the mandate, Application is submitted successful.